You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

404 Results
Blog post
In honour of Patient Experience Week, CCO patient advisor Deb K. shares her thoughts on how healthcare providers can communicate more effectively...
Dec 1969
Document
Guidelines and Advice
Blog post
Passionate. Committed. Patient-focused. These are just a few of the words that have been used to describe this year’s Human Touch Award recipients in...
Sep 2018
Blog post
While cancer drug shortages are not new, they are more frequent than ever. The reality today is that one or more cancer drugs may be in short supply...
Sep 2018
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria

Pages